Search | Clinical Trials Finder

Conditions: Hypercholesterolemia
Interventions: REGN727(SAR236553); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Cincinnati, Ohio • Knoxville, Tennessee

Conditions: Saphenous Vein Graft Atherosclerosis
Interventions: Alirocumab 150 MG/ML subcutaneous injection, Matching Placebo subcutaneous injection; Drug
Lead sponsor: Minneapolis Heart Institute Foundation; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: San Francisco, California • Atlanta, Georgia • Minneapolis, Minnesota + 1 more

Conditions: Healthy Volunteers
Interventions: REGN727, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Sepsis
Interventions: Alirocumab, Placebo; Drug
Lead sponsor: Jonathan Sevransky; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Healthy Subjects, Pharmacokinetics, Pharmacodynamics
Interventions: Evolocumab, Alirocumab, Placebo; Biological
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Hypercholesterolemia
Interventions: Evinacumab, Matching placebo, Background Lipid Modifying Therapy (LMT); Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 23
States / cities: Los Angeles, California • Newport Beach, California • Boca Raton, Florida + 19 more

Conditions: Hypercholesterolemia
Interventions: alirocumab SAR236553 (REGN727); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Non Small Cell Lung Cancer
Interventions: Alirocumab, Cemiplimab, Chemotherapy; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Myocardial Infarction, Hypercholesterolemia
Interventions: alirocumab, placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hypercholesterolemia
Interventions: Praluent (Alirocumab), Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 2,176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 73
States / cities: Auburn, Alabama • Birmingham, Alabama • Mobile, Alabama + 63 more

Conditions: Melanoma
Interventions: Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran); Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 55 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events
Interventions: Alirocumab, Comparator: No PCSK9i Therapy (either mAb or siRNA); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 4,545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for alirocumab), Ezetimibe, Placebo (for ezetimibe), Lipid Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 58
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Alcohol Associated Liver Disease, Heavy Drinking Behavior
Interventions: Alirocumab, Placebo; Drug · Other
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Alirocumab and Cemiplimab; Combination Product
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Tampa, Florida • Durham, North Carolina

Conditions: Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
Interventions: Alirocumab, Placebo Matched to Alirocumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 11
States / cities: Mission Viejo, California • Newport Beach, California • Thousand Oaks, California + 8 more

Conditions: Dyslipidemia
Interventions: Alirocumab, Statins, Ezetimibe, Fenofibrate, Nicotinic acid, Omega-3 fatty acids, Antihyperglycemic Drug; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 57
States / cities: Little Rock, Arkansas • Fresno, California • Huntington Beach, California + 51 more

Conditions: Hypercholesterolaemia
Interventions: alirocumab SAR236553 (REGN727), statins, ezetimibe, cholestyramine, fenofibrate, omega-3 fatty acids, nicotinic acid; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: St Louis, Missouri • Charlotte, North Carolina • Cincinnati, Ohio

Conditions: Dyslipidemias, Cardiovascular Diseases, HIV Infections
Interventions: Alirocumab, Placebo; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hemodialysis, Peritoneal Dialysis, Hypercholesterolemia, Atherosclerotic Disease
Interventions: Alirocumab 150 MG/ML [Praluent]; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypercholesterolemia
Interventions: alirocumab SAR236553 (REGN727); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Homozygous Familial Hypercholesterolemia
Interventions: Alirocumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Boca Raton, Florida • New York, New York • Cincinnati, Ohio + 1 more

Conditions: Hypercholesterolaemia
Interventions: Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 14
States / cities: Bell Gardens, California • Newport Beach, California • Northridge, California + 8 more

Search by objective public record fields.

Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin

The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial

Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy Volunteers

Alirocumab in Patients with Sepsis

Pharmacodynamic Biomarkers to Support Biosimilar Development: PCSK9 Inhibitors

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)

TOP 2301: Neoadjuvant Chemo for NSCLC

Alirocumab in Patients With Acute Myocardial Infarction

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma

Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene

Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers

PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)

Alirocumab in Patients on a Stable Dialysis Regimen

Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects

Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)